c 1311 has been researched along with Hemolysis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beijnen, JH; Buluran, JN; den Brok, MW; Grieshaber, CK; Harms, R; Harvey, MD; Nuijen, B | 1 |
| Jóźwiak, Z; Pacholska, M; Szwarocka, A | 1 |
2 other study(ies) available for c 1311 and Hemolysis
| Article | Year |
|---|---|
Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility.
Topics: Aminoacridines; Antineoplastic Agents; Buffers; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Incompatibility; Drug Stability; Hemolysis; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Infusions, Intravenous | 2005 |
The effects of imidazoacridinones, new antineoplastic agents, on the human erythrocyte membrane.
Topics: Aminoacridines; Antineoplastic Agents; Biological Transport; Cytoskeletal Proteins; Electron Spin Resonance Spectroscopy; Erythrocyte Membrane; Hemolysis; Humans; Membrane Fluidity; Protein Conformation; Temperature | 1997 |